The Journal for ImmunoTherapy of Cancer

is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.

Impact Factor: 12.469
Citescore: 14.3
All metrics >>

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).

EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board

Current Issue

Highlighted Articles

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors

1 July 2022

Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature

1 July 2022

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry

1 July 2022

Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response

1 July 2022

Authors

The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.

The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.

Information is also provided on editorial policy, Open Access fees and formatting.

Author information Submit a paper

Twitter Feed

COVID-19 and Cancer Immunotherapy

Review:

JAK inhibitors and COVID-19

22 April 2022

Review:

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

16 July 2021

Review:

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

11 June 2021

Review:

Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients

11 June 2021

Review:

Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

13 May 2021

Latest Articles

Case report:

Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report

6 October 2022

Basic tumor immunology:

CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein

5 October 2022

Basic tumor immunology:

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy

3 October 2022

Clinical/translational cancer immunotherapy:

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization

3 October 2022

Most Read Articles

Case report:

Spontaneous tumor regression following COVID-19 vaccination

3 March 2022

Clinical/translational cancer immunotherapy:

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, sing…

21 January 2022

Review:

Severity of COVID-19 in patients with lung cancer: evidence and challenges

18 March 2021

Immunotherapy biomarkers:

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

21 July 2022

Position article and guidelines:

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

25 June 2021

Altmetrics

Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
7 February 2022

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
19 June 2022

Spontaneous tumor regression following COVID-19 vaccination
3 March 2022

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
21 July 2022

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
15 December 2020

What Our Editors Are Reading

In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.

JITC Reading List

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Explore SITC’s cancer immunotherapy community at sitcancer.org and become a member to take advantage of SITC’s member benefit of 50% off APCs for all articles submitted and accepted in JITC in 2022.